Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-222 in advanced solid tumors
NCT05252416Phase 1Terminated
- Sponsor
- Blueprint Medicines
- Start
- Apr 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of BLU-222 in breast cancer, ovarian cancer, endometrial cancer (EC) and 3 more (4 arms), sponsored by Blueprint Medicines. Primary endpoints: Maximum Tolerated Dose at 21 months, Recommended Phase 2 Dose at 21 months and 2 more. Started Apr 2022; status: terminated.
02
Drugs
BLU-222
03
Conditions
breast cancerovarian cancerendometrial cancer (EC)gastric cancer (GC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT05252416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252416.